This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 1454 |
membrane oxygenation | 1139 |
extracorporeal membrane | 1120 |
mechanical ventilation | 951 |
care unit | 777 |
critically ill | 760 |
acute respiratory | 752 |
respiratory failure | 699 |
septic shock | 641 |
respiratory distress | 614 |
distress syndrome | 550 |
ill patients | 539 |
critical care | 417 |
cardiac arrest | 390 |
patients admitted | 345 |
risk factors | 332 |
hospital mortality | 323 |
two groups | 321 |
icu admission | 307 |
life support | 295 |
organ failure | 279 |
mortality rate | 268 |
ecmo support | 263 |
mean age | 262 |
control group | 259 |
icu patients | 254 |
extracorporeal life | 251 |
blood flow | 247 |
severe ards | 241 |
mg kg | 238 |
ethics regulations | 238 |
icu stay | 232 |
severe acute | 227 |
ml kg | 225 |
cardiogenic shock | 223 |
mechanically ventilated | 212 |
blood pressure | 211 |
lung injury | 210 |
sofa score | 208 |
adult patients | 203 |
apache ii | 201 |
significantly higher | 198 |
tidal volume | 195 |
pao fio | 193 |
observational study | 192 |
heart failure | 190 |
retrospective study | 188 |
cardiac output | 188 |
ards patients | 183 |
prone positioning | 182 |
cardiac surgery | 179 |
care units | 172 |
patients received | 170 |
university hospital | 169 |
lung transplantation | 164 |
prospective study | 164 |
multivariate analysis | 162 |
significant difference | 160 |
arterial pressure | 158 |
cohort study | 157 |
renal replacement | 155 |
renal failure | 153 |
day mortality | 153 |
arterial blood | 150 |
patients receiving | 150 |
study period | 149 |
patients treated | 148 |
replacement therapy | 147 |
statistically significant | 146 |
heart rate | 145 |
logistic regression | 144 |
gas exchange | 140 |
central venous | 135 |
coronavirus disease | 131 |
one patient | 130 |
significant differences | 127 |
factors associated | 126 |
ventilated patients | 125 |
critical illness | 125 |
septic patients | 124 |
ng ml | 123 |
kidney injury | 122 |
included patients | 122 |
patients undergoing | 121 |
ecmo patients | 121 |
among patients | 120 |
patients without | 118 |
brain injury | 118 |
median age | 117 |
survival rate | 117 |
pulmonary artery | 116 |
kg min | 116 |
emergency department | 116 |
airway pressure | 115 |
respiratory rate | 115 |
mean arterial | 114 |
ii score | 114 |
multiple organ | 114 |
saps ii | 113 |
acute kidney | 113 |
severe respiratory | 112 |
years old | 112 |
pg ml | 112 |
two patients | 109 |
support organization | 108 |
high mortality | 108 |
organ dysfunction | 108 |
severe sepsis | 107 |
vv ecmo | 107 |
consecutive patients | 107 |
prone position | 106 |
present study | 105 |
hospital stay | 105 |
high risk | 105 |
left ventricular | 105 |
significantly lower | 103 |
statistical analysis | 103 |
nitric oxide | 103 |
associated pneumonia | 102 |
risk factor | 101 |
doc id | 100 |
oxygen saturation | 100 |
blood gas | 100 |
cord uid | 100 |
icu discharge | 99 |
antibiotic therapy | 98 |
ml min | 97 |
ecmo initiation | 97 |
myocardial infarction | 95 |
venovenous extracorporeal | 95 |
systematic review | 94 |
clinical outcomes | 94 |
inflammatory response | 92 |
carbon dioxide | 91 |
primary outcome | 91 |
pediatric patients | 90 |
hospital discharge | 90 |
adult respiratory | 89 |
mm hg | 88 |
icu mortality | 87 |
patients died | 87 |
novel coronavirus | 87 |
least one | 86 |
shock patients | 86 |
lactate levels | 86 |
ecmo team | 86 |
performed using | 85 |
first days | 85 |
controlled trial | 84 |
informed consent | 84 |
fio ratio | 84 |
prospective observational | 83 |
regression analysis | 83 |
body weight | 83 |
spontaneous breathing | 83 |
blood samples | 83 |
univariate analysis | 83 |
acute lung | 82 |
poor outcome | 82 |
first hours | 81 |
cardiac index | 81 |
trauma patients | 81 |
expiratory pressure | 81 |
mg dl | 80 |
pulmonary hypertension | 80 |
independently associated | 79 |
blood gases | 78 |
driving pressure | 78 |
pediatric intensive | 78 |
clinical characteristics | 78 |
significant increase | 78 |
pulmonary embolism | 77 |
ventilatory support | 77 |
higher mortality | 77 |
right ventricular | 76 |
ecmo group | 76 |
cardiopulmonary bypass | 76 |
positive end | 75 |
protective ventilation | 75 |
retrospective cohort | 74 |
mortality rates | 74 |
cardiopulmonary resuscitation | 74 |
patients requiring | 74 |
care medicine | 73 |
invasive ventilation | 73 |
increased risk | 73 |
long term | 72 |
clinical course | 72 |
significantly associated | 72 |
hospital cardiac | 71 |
group i | 70 |
nosocomial infections | 70 |
adverse events | 70 |
oxygen delivery | 69 |
respiratory syndrome | 69 |
venovenous ecmo | 69 |
pressure support | 68 |
invasive mechanical | 68 |
three patients | 68 |
within hours | 68 |
side effects | 67 |
acquired pneumonia | 67 |
vascular resistance | 67 |
partial pressure | 66 |
respiratory system | 66 |
year period | 66 |
acute renal | 66 |
randomized controlled | 65 |
increased mortality | 65 |
predictive value | 65 |
heart disease | 63 |
tidal volumes | 63 |
coronary artery | 63 |
circulatory support | 63 |
pulmonary vascular | 63 |
pulmonary edema | 63 |
average age | 62 |
ejection fraction | 62 |
odds ratio | 62 |
endotracheal tube | 61 |
neurological outcome | 61 |
renal function | 60 |
hemodynamic parameters | 60 |
bacterial pneumonia | 60 |
patients hospitalized | 60 |
prognostic factors | 60 |
th day | 60 |
traumatic brain | 59 |
case report | 59 |
hospitalized patients | 59 |
significantly different | 59 |
study included | 59 |
inclusion criteria | 59 |
four patients | 58 |
blood cultures | 58 |
sex ratio | 57 |
patients required | 57 |
clinical trial | 57 |
venous extracorporeal | 57 |
interquartile range | 57 |
pseudomonas aeruginosa | 57 |
ecmo therapy | 57 |
blood culture | 57 |
significantly increased | 56 |
venous ecmo | 56 |
plasma levels | 55 |
age years | 55 |
month period | 55 |
clinical practice | 55 |
ecmo circuit | 54 |
retrospective analysis | 54 |
case series | 54 |
va ecmo | 54 |
international congresses | 54 |
lactate level | 54 |
lung disease | 53 |
respiratory tract | 53 |
clinical data | 53 |
blood loss | 53 |
icu length | 53 |
red blood | 53 |
health care | 52 |
reactive protein | 52 |
exclusion criteria | 52 |
ethics committee | 52 |
venous blood | 52 |
five patients | 52 |
cardiac failure | 52 |
one case | 52 |
eight patients | 51 |
received ecmo | 51 |
overall mortality | 51 |
significant decrease | 51 |
patients included | 51 |
pilot study | 51 |
roc curve | 51 |
liver failure | 51 |
medical icu | 51 |
mortality risk | 51 |
successfully weaned | 50 |
surgical patients | 50 |
jugular vein | 50 |
failure assessment | 50 |
clinical features | 50 |
glasgow coma | 50 |
internal jugular | 50 |
co removal | 50 |
venous pressure | 49 |
enteral nutrition | 49 |
lung transplant | 49 |
significant correlation | 49 |
commonly used | 49 |
acute myocardial | 49 |
data collection | 49 |
blood lactate | 49 |
sequential organ | 49 |
ct scan | 48 |
elderly patients | 48 |
poor prognosis | 48 |
pulmonary disease | 48 |
previous studies | 48 |
nervous system | 48 |
circulatory failure | 48 |
liver transplantation | 48 |
cardiac function | 48 |
flow rate | 48 |
serum creatinine | 48 |
demographic data | 48 |
data suggest | 48 |
mean duration | 48 |
medical intensive | 48 |
computed tomography | 47 |
confidence interval | 47 |
acute physiology | 47 |
regression model | 47 |
median time | 47 |
dans le | 47 |
right atrium | 47 |
brain death | 47 |
congenital heart | 47 |
femoral vein | 46 |
postoperative period | 46 |
per patient | 46 |
study conducted | 46 |
fluid resuscitation | 46 |
ventilator settings | 46 |
hospital length | 45 |
fluid balance | 45 |
receiver operating | 45 |
median duration | 45 |
within days | 45 |
clinical signs | 45 |
study aimed | 45 |
mechanical power | 45 |
measured using | 44 |
syndrome coronavirus | 44 |
parenteral nutrition | 44 |
induced lung | 44 |
venoarterial extracorporeal | 44 |
head injury | 44 |
severity score | 44 |
multidisciplinary team | 44 |
whole blood | 44 |
independent risk | 44 |
continuous renal | 43 |
staphylococcus aureus | 43 |
infected patients | 43 |
results suggest | 43 |
stroke volume | 43 |
fluid responsiveness | 43 |
prospective cohort | 43 |
united states | 43 |
six patients | 43 |
ecmo treatment | 43 |
patients underwent | 43 |
public health | 43 |
copd patients | 43 |
survival rates | 43 |
randomized trial | 42 |
ill children | 42 |
vena cava | 42 |
lung compliance | 42 |
predictive factors | 42 |
severe covid | 42 |
oxygen consumption | 42 |
metabolic acidosis | 42 |
ventricular assist | 42 |
group ii | 42 |
platelet count | 42 |
secondary outcomes | 41 |
central nervous | 41 |
baseline characteristics | 41 |
ecmo centers | 41 |
plateau pressure | 41 |
urine output | 41 |
center study | 41 |
statistical significance | 41 |
refractory cardiogenic | 41 |
inhaled nitric | 41 |
patient population | 40 |
hoc analysis | 40 |
higher risk | 40 |
analysis showed | 40 |
lung protective | 40 |
extubation failure | 40 |
blood cells | 40 |
may lead | 40 |
arterial oxygen | 40 |
patients presented | 40 |
heart transplantation | 40 |
prognostic value | 40 |
seven patients | 40 |
right heart | 40 |
may also | 40 |
respiratory support | 40 |
oxygen therapy | 40 |
pacientes con | 40 |
kg day | 40 |
obese patients | 40 |
inspiratory pressure | 40 |
clinical trials | 39 |
two cases | 39 |
randomized clinical | 39 |
respiratory mechanics | 39 |
first day | 39 |
collected data | 39 |
severity scores | 39 |
overall survival | 39 |
ecmo flow | 39 |
leading cause | 39 |
nine patients | 39 |
pulmonary arterial | 39 |
infectious diseases | 39 |
care patients | 39 |
post hoc | 39 |
linear regression | 39 |
adverse effects | 39 |
systemic inflammatory | 39 |
gestational age | 39 |
tissue oxygenation | 39 |
medical records | 39 |
en cas | 39 |
enteral feeding | 38 |
randomised controlled | 38 |
virus infection | 38 |
longer duration | 38 |
one hundred | 38 |
single center | 38 |
severe adult | 38 |
healthy volunteers | 38 |
mechanical circulatory | 38 |
coma scale | 38 |
cmv reactivation | 38 |
mcg kg | 38 |
minute ventilation | 38 |
continuous infusion | 37 |
preterm infants | 37 |
study group | 37 |
ecmo may | 37 |
tertiary care | 37 |
authors declare | 37 |
determine whether | 37 |
oxygenation support | 37 |
increased significantly | 37 |
severe influenza | 37 |
patients may | 37 |
retrospective observational | 37 |
pulmonary function | 37 |
surgical icu | 36 |
ten patients | 36 |
blood cell | 36 |
supine position | 36 |
middle east | 36 |
related complications | 36 |
patient outcomes | 36 |
ecmo cannulation | 36 |
blood volume | 36 |
teaching hospital | 36 |
patients supported | 36 |
assist device | 36 |
bacterial meningitis | 36 |
patients presenting | 36 |
east respiratory | 36 |
neuromuscular blockade | 36 |
arterial extracorporeal | 36 |
rescue therapy | 36 |
study showed | 36 |
endotracheal intubation | 35 |
patient characteristics | 35 |
inspired oxygen | 35 |
cancer patients | 35 |
per day | 35 |
patients suffering | 35 |
intracranial hypertension | 35 |
written informed | 35 |
per year | 35 |
refractory hypoxemia | 35 |
disease severity | 35 |
analyzed using | 35 |
avian influenza | 35 |
membrane oxygenator | 35 |
hospital admission | 35 |
primary endpoint | 35 |
extracorporeal circulation | 35 |
systolic blood | 35 |
emergency room | 35 |
significantly reduced | 34 |
medical center | 34 |
last years | 34 |
nutritional support | 34 |
receiving ecmo | 34 |
antimicrobial therapy | 34 |
hospital survival | 34 |
heart surgery | 34 |
descriptive study | 34 |
high incidence | 34 |
bacterial infection | 34 |
blood transfusion | 34 |
right ventricle | 34 |
physiology score | 34 |
mixed venous | 34 |
venous catheter | 34 |
assessed using | 34 |
extracorporeal co | 34 |
patients aged | 34 |
may help | 34 |
continuous variables | 34 |
niv failure | 33 |
simplified acute | 33 |
ecmo duration | 33 |
bronchoalveolar lavage | 33 |
prospectively collected | 33 |
support ventilation | 33 |
hemodynamic instability | 33 |
standard deviation | 33 |
mortality among | 33 |
chronic obstructive | 33 |
individual patient | 33 |
high morbidity | 33 |
eolia trial | 33 |
endothelial cells | 33 |
fluid administration | 33 |
viral pneumonia | 33 |
kidney disease | 33 |
esophageal pressure | 33 |
multicenter study | 33 |
conventional ventilatory | 33 |
atrial fibrillation | 33 |
study including | 33 |
compared using | 33 |
underlying disease | 32 |
patient data | 32 |
may result | 32 |
term outcomes | 32 |
research support | 32 |
medical care | 32 |
multiorgan failure | 32 |
sepsis campaign | 32 |
healthy subjects | 32 |
body temperature | 32 |
acute phase | 32 |
three days | 32 |
medical history | 32 |
studied patients | 32 |
requiring ecmo | 32 |
body mass | 32 |
general anesthesia | 32 |
chest pain | 32 |
normal range | 32 |
selected patients | 32 |
chest wall | 32 |
ischemic stroke | 32 |
support scientific | 31 |
preliminary results | 31 |
venous return | 31 |
significant reduction | 31 |
successful weaning | 31 |
negative predictive | 31 |
gas analysis | 31 |
peak inspiratory | 31 |
caso di | 31 |
required mechanical | 31 |
scientific studies | 31 |
ang ii | 31 |
categorical variables | 31 |
extracorporeal support | 31 |
spontaneous circulation | 31 |
mass index | 31 |
surviving sepsis | 31 |
may improve | 31 |
burn patients | 31 |
pulmonary infection | 31 |
creatinine clearance | 31 |
corporeal membrane | 31 |
data analysis | 31 |
ventricular function | 31 |
exact test | 31 |
operating characteristic | 31 |
infectious complications | 31 |
fluid challenge | 30 |
fl ow | 30 |
groups according | 30 |
vital signs | 30 |
treated patients | 30 |
intubated patients | 30 |
dilated cardiomyopathy | 30 |
related ards | 30 |
decision making | 30 |
higher incidence | 30 |
prone ventilation | 30 |
poor outcomes | 30 |
operating room | 30 |
sample size | 30 |
nosocomial infection | 30 |
ecmo weaning | 30 |
positive blood | 30 |
du circuit | 30 |
year old | 30 |
controlled trials | 30 |
one hour | 30 |
immunocompromised patients | 30 |
obstructive pulmonary | 30 |
transthoracic echocardiography | 30 |
liver disease | 30 |
study shows | 30 |
term survival | 30 |
lung ultrasound | 30 |
vasoactive drugs | 30 |
lower respiratory | 30 |
transplant recipients | 29 |
jugular bulb | 29 |
days later | 29 |
unfractionated heparin | 29 |
including patients | 29 |
systemic inflammation | 29 |
patients developed | 29 |
elso registry | 29 |
team group | 29 |
severe head | 29 |
left ventricle | 29 |
risk patients | 29 |
artery bypass | 29 |
influenza virus | 29 |
aki stage | 29 |
patient safety | 29 |
flow rates | 29 |
early diagnosis | 29 |
status epilepticus | 29 |
data collected | 29 |
patients showed | 29 |
high frequency | 29 |
bleeding complications | 29 |
extracorporeal cardiopulmonary | 29 |
birth weight | 29 |
significant improvement | 28 |
urinary tract | 28 |
pleural effusion | 28 |
blood products | 28 |
mean values | 28 |
membrane lung | 28 |
pulmonary blood | 28 |
ecmo programs | 28 |
may contribute | 28 |
review board | 28 |
conventional mechanical | 28 |
randomly assigned | 28 |
year mortality | 28 |
prospective randomized | 28 |
disseminated intravascular | 28 |
arterial lactate | 28 |
patients survived | 28 |
blood glucose | 28 |
requiring mechanical | 28 |
tracheal intubation | 28 |
prolonged mechanical | 28 |
one year | 28 |
serum lactate | 28 |
high level | 28 |
ecmonet score | 28 |
united kingdom | 28 |
total number | 28 |
investigate whether | 28 |
coronary angiography | 28 |
study population | 28 |
hypoxemic respiratory | 28 |
protective effect | 28 |
patient selection | 28 |
multivariate logistic | 28 |
surface area | 28 |
spinal cord | 28 |
centrifugal pump | 27 |
organ donation | 27 |
previously reported | 27 |
support versus | 27 |
non invasive | 27 |
low tidal | 27 |
intravascular coagulation | 27 |
artery catheter | 27 |
gene expression | 27 |
main cause | 27 |
sepsis patients | 27 |
organ support | 27 |
patients infected | 27 |
versus extracorporeal | 27 |
abdominal surgery | 27 |
group compared | 27 |
cirrhotic patients | 27 |
en el | 27 |
predict mortality | 27 |
scoring system | 27 |
murray score | 27 |
renal dysfunction | 27 |
conventional therapy | 27 |
systolic function | 27 |
inotropic support | 27 |
common cause | 27 |
tract infection | 27 |
clinical management | 27 |
patient died | 27 |
sweep gas | 26 |
respiratory insufficiency | 26 |
respiratory syncytial | 26 |
graft dysfunction | 26 |
di assistenza | 26 |
success rate | 26 |
important role | 26 |
los pacientes | 26 |
nursing staff | 26 |
volume expansion | 26 |
shockable rhythm | 26 |
acute exacerbation | 26 |
incidence rate | 26 |
severe hypoxemia | 26 |
oxygenated blood | 26 |
steady state | 26 |
per minute | 26 |
airway management | 26 |
high doses | 26 |
patient care | 26 |
hemodynamic monitoring | 26 |
correlation coefficient | 26 |
hours later | 26 |
ill adults | 26 |
lower mortality | 26 |
noninvasive ventilation | 26 |
control study | 26 |
gold standard | 26 |
medical staff | 26 |
gas flow | 26 |
immune response | 26 |
predicted body | 26 |
medical treatment | 25 |
clinically relevant | 25 |
acinetobacter baumannii | 25 |
carotid artery | 25 |
widely used | 25 |
neuromuscular blockers | 25 |
liver function | 25 |
emergency medicine | 25 |
institutional affiliations | 25 |
syndrome extracorporeal | 25 |
health problem | 25 |
diaphragm dysfunction | 25 |
acute pulmonary | 25 |
published maps | 25 |
lung function | 25 |
springer nature | 25 |
monocentric study | 25 |
remains unclear | 25 |
muscle weakness | 25 |
brain damage | 25 |
remains neutral | 25 |
intracranial hemorrhage | 25 |
world health | 25 |
two hours | 25 |
significantly decreased | 25 |
nature remains | 25 |
clinical outcome | 25 |
injury severity | 25 |
care med | 25 |
jurisdictional claims | 25 |
significant changes | 25 |
thrombotic complications | 25 |
systemic vascular | 25 |
showed significant | 24 |
france correspondence | 24 |
fluid management | 24 |
institutional review | 24 |
diabetes mellitus | 24 |
well tolerated | 24 |
economic assessment | 24 |
severe pulmonary | 24 |
arterial ph | 24 |
high flow | 24 |
three groups | 24 |
respiratoria aguda | 24 |
peripheral blood | 24 |
mean value | 24 |
improved survival | 24 |
group showed | 24 |
general hospital | 24 |
le plus | 24 |
data regarding | 24 |
thromboembolic events | 24 |
chest tube | 24 |
square test | 24 |
surgical procedures | 24 |
respiratory disease | 24 |
within minutes | 24 |
inhalation injury | 24 |
free days | 24 |
frozen plasma | 24 |
family members | 24 |
cerebral blood | 24 |
left heart | 24 |
negative bacilli | 24 |
ecmo use | 24 |
premature infants | 24 |
loading dose | 24 |
flow nasal | 24 |
primary objective | 24 |
care management | 24 |
chronic respiratory | 24 |
stage aki | 23 |
therapeutic management | 23 |
del paziente | 23 |
high rate | 23 |
ecmo blood | 23 |
mean blood | 23 |
nasal cannula | 23 |
music therapy | 23 |
two different | 23 |
multiple trauma | 23 |
weaning failure | 23 |
identify patients | 23 |
respiratory function | 23 |
pk pd | 23 |
discharged alive | 23 |
neurological complications | 23 |
base excess | 23 |
differ significantly | 23 |
flow cytometry | 23 |
main causes | 23 |
diagnostic performance | 23 |
intervention group | 23 |
acute liver | 23 |
acquired weakness | 23 |
average time | 23 |
current study | 23 |
term outcome | 23 |
serum samples | 23 |
patients needed | 23 |
patient management | 23 |
partial thromboplastin | 23 |
hemorrhagic complications | 23 |
observational cohort | 23 |
therapeutic intervention | 23 |
high levels | 23 |
aguda grave | 23 |
positive predictive | 23 |
di una | 23 |
case reports | 23 |
severely ill | 23 |
respiratory infection | 23 |
antiviral therapy | 23 |
ventilation strategy | 23 |
chronic kidney | 23 |
refractory cardiac | 23 |
con el | 23 |
first time | 23 |
time course | 23 |
multicentre randomised | 23 |
pump speed | 23 |
recent years | 23 |
polymerase chain | 23 |
flusso di | 23 |
aspiration pneumonia | 22 |
berlin definition | 22 |
positive correlation | 22 |
frequently used | 22 |
ventricular ejection | 22 |
patients diagnosed | 22 |
standard care | 22 |
significant association | 22 |
vv ecls | 22 |
white blood | 22 |
new zealand | 22 |
probably due | 22 |
drug administration | 22 |
le circuit | 22 |
severe pneumonia | 22 |
determined using | 22 |
died within | 22 |
receiving venovenous | 22 |
primary graft | 22 |
lung cancer | 22 |
functional status | 22 |
thrombin generation | 22 |
transesophageal echocardiography | 22 |
study aims | 22 |
sofa scores | 22 |
analysed using | 22 |
patients discharged | 22 |
dificultad respiratoria | 22 |
citrate anticoagulation | 22 |
packed red | 22 |
enrolled patients | 22 |
syncytial virus | 22 |
multicenter prospective | 22 |
hepatic encephalopathy | 22 |
pandemic influenza | 22 |
ml vs | 22 |
median length | 22 |
inflammatory mediators | 22 |
surgery patients | 22 |
predicting survival | 22 |
hbv dna | 22 |
defined according | 22 |
lg kg | 22 |
well known | 22 |
crit care | 22 |
additional file | 22 |
dioxide removal | 22 |
femoral artery | 22 |
thromboplastin time | 22 |
prism score | 22 |
des patients | 22 |
induced acute | 22 |
mean apache | 22 |
high dose | 22 |
ill patient | 22 |
chain reaction | 22 |
ii scores | 22 |
significantly correlated | 22 |
intracranial pressure | 22 |
three different | 22 |
head trauma | 22 |
surgical intensive | 22 |
ill covid | 22 |
cell count | 22 |
renal impairment | 22 |
cerebral oxygenation | 22 |
right internal | 22 |
present case | 21 |
wide range | 21 |
organ systems | 21 |
systemic arterial | 21 |
organ failures | 21 |
abdominal pain | 21 |
rank test | 21 |
organization registry | 21 |
results indicate | 21 |
patients ventilated | 21 |
fresh frozen | 21 |
health organization | 21 |
multivariate regression | 21 |
extracorporeal lung | 21 |
prospective studies | 21 |
preventive measures | 21 |
artery pressure | 21 |
immune system | 21 |
continuous monitoring | 21 |
antibiotic treatment | 21 |
normal saline | 21 |
hemorrhagic shock | 21 |
icu staff | 21 |
nosocomial pneumonia | 21 |
vascular access | 21 |
hypoxemic patients | 21 |
acute pancreatitis | 21 |
oxygenation index | 21 |
recent studies | 21 |
serum levels | 21 |
positive airway | 21 |
extra corporeal | 21 |
spontaneously breathing | 21 |
cardiopulmonary failure | 21 |
clinical study | 21 |
even though | 21 |
time spent | 21 |
severe patients | 21 |
independent predictor | 21 |
della cannula | 21 |
time points | 21 |
inferior vena | 21 |
significantly improved | 21 |
mean airway | 21 |
making process | 21 |
response syndrome | 21 |
time period | 21 |
acute brain | 21 |
nursing care | 20 |
tissue perfusion | 20 |
dead space | 20 |
cardiac surgical | 20 |
lung volume | 20 |
map mmhg | 20 |
peep level | 20 |
severe trauma | 20 |
du patient | 20 |
findings suggest | 20 |
good outcome | 20 |
assist devices | 20 |
venoarterial ecmo | 20 |
patients compared | 20 |
lower tidal | 20 |
laboratory data | 20 |
average length | 20 |
common complication | 20 |
con sospecha | 20 |
artery disease | 20 |
first three | 20 |
cardiac dysfunction | 20 |
retrospectively reviewed | 20 |
first week | 20 |
airway spasm | 20 |
negative pressure | 20 |
dei pazienti | 20 |
significantly longer | 20 |
hospital death | 20 |
first group | 20 |
massive pulmonary | 20 |
heparin infusion | 20 |
ecmo program | 20 |
beneficial effect | 20 |
clinical decision | 20 |
pressure ventilation | 20 |
breathing trial | 20 |
icu survivors | 20 |
ecmo center | 20 |
fluid overload | 20 |
supplementary material | 20 |
clinical parameters | 20 |
paediatric intensive | 20 |
chronic health | 20 |
natriuretic peptide | 20 |
severe cases | 20 |
acute circulatory | 20 |
rv function | 20 |
care bundle | 20 |
identify factors | 20 |
mean time | 20 |
stem cell | 20 |
weaned group | 20 |
decreased significantly | 20 |
evaluated using | 20 |
ventilator associated | 20 |
conventional ventilation | 20 |
plasma concentration | 20 |
diaphragmatic hernia | 20 |
grave refractaria | 20 |
children admitted | 20 |
assess whether | 20 |
myocardial dysfunction | 20 |
activated partial | 20 |
conventional management | 20 |
aortic balloon | 20 |
care physicians | 19 |
msc infusion | 19 |
hepatic failure | 19 |
dysfunction syndrome | 19 |
study performed | 19 |
discharged home | 19 |
major bleeding | 19 |
systolic dysfunction | 19 |
improve survival | 19 |
table shows | 19 |
infected pneumonia | 19 |
ex vivo | 19 |
arterial ecmo | 19 |
small sample | 19 |
resource utilization | 19 |
icu los | 19 |
mean sd | 19 |
burned patients | 19 |
nitrogen balance | 19 |
iu ml | 19 |
ventricular dysfunction | 19 |
icu nurses | 19 |
cardiopulmonary support | 19 |
one third | 19 |
du sang | 19 |
significant risk | 19 |
following parameters | 19 |
inflammatory cytokines | 19 |
prospectively studied | 19 |
pulse oximetry | 19 |
care doi | 19 |
poor neurological | 19 |
mobile ecmo | 19 |
weaning process | 19 |
breathing pattern | 19 |
admitted patients | 19 |
icu physicians | 19 |
early detection | 19 |
fluid infusion | 19 |
preliminary data | 19 |
healthy controls | 19 |
may provide | 19 |
national health | 19 |
results showed | 19 |
prospective multicenter | 19 |
und die | 19 |
di drenaggio | 19 |
failure requiring | 19 |
unfavorable outcome | 19 |
early stage | 19 |
acuerdo con | 19 |
previous study | 19 |
lung damage | 19 |
il est | 19 |
published data | 19 |
infrared spectroscopy | 19 |
short term | 19 |
ug ml | 19 |
general icu | 19 |
early initiation | 19 |
end expiratory | 19 |
hypercapnic respiratory | 18 |
hemodynamic status | 18 |
hemodynamic variables | 18 |
undergoing cardiac | 18 |
chronic renal | 18 |
congestive heart | 18 |
cette technique | 18 |
bone marrow | 18 |
scoring systems | 18 |
mainland china | 18 |
emergency medical | 18 |
randomized study | 18 |
transplant recipient | 18 |
several studies | 18 |
avec des | 18 |
arterial oxygenation | 18 |
median sofa | 18 |
klebsiella pneumoniae | 18 |
beneficial effects | 18 |
remaining patients | 18 |
patients suffered | 18 |
statistically different | 18 |
medical university | 18 |
general population | 18 |
clotting time | 18 |
every hours | 18 |
survival benefit | 18 |
low flow | 18 |
internal medicine | 18 |
mean length | 18 |
blood sampling | 18 |
year survival | 18 |
therapeutic hypothermia | 18 |
control patients | 18 |
operative period | 18 |
outcome data | 18 |
di ecmo | 18 |
may occur | 18 |
cerebral perfusion | 18 |
early phase | 18 |
airway pressures | 18 |
fio mmhg | 18 |
clinical presentation | 18 |
group patients | 18 |
whitney test | 18 |
ecmo network | 18 |
energy expenditure | 18 |
plus souvent | 18 |
kg hr | 18 |
hematological malignancies | 18 |
note springer | 18 |
also recorded | 18 |
placebo group | 18 |
second group | 18 |
converting enzyme | 18 |
wedge pressure | 18 |
hepatic dysfunction | 18 |
multivariable logistic | 18 |
unsuccessfully weaned | 18 |
icu admissions | 18 |
carbon monoxide | 18 |
severe asthma | 18 |
selection criteria | 18 |
acute hypoxemic | 18 |
term mortality | 18 |
acute coronary | 18 |
significant morbidity | 18 |
total bilirubin | 18 |
mechanical support | 18 |
percutaneous coronary | 18 |
organ function | 18 |
propensity score | 18 |
ards due | 18 |
critical patients | 18 |
breaths min | 18 |
competing interests | 18 |
reperfusion injury | 18 |
group without | 18 |
di un | 18 |
bacterial resistance | 18 |
oxygen supply | 17 |
demographic characteristics | 17 |
rv dysfunction | 17 |
serious complications | 17 |
infection control | 17 |
higher levels | 17 |
qsofa score | 17 |
citrate accumulation | 17 |
hazard ratio | 17 |
awake ecmo | 17 |
prolonged icu | 17 |
requiring extracorporeal | 17 |
conventional treatment | 17 |
surgical procedure | 17 |
small number | 17 |
day survival | 17 |
results patients | 17 |
lung recruitment | 17 |
clinical studies | 17 |
excluded patients | 17 |
required ecmo | 17 |
coronary intervention | 17 |
chart review | 17 |
aortic valve | 17 |
pulmonary congestion | 17 |
diabetic ketoacidosis | 17 |
retrospective review | 17 |
without significant | 17 |
viral infections | 17 |
twelve patients | 17 |
may cause | 17 |
major surgery | 17 |
multicenter cohort | 17 |
positive patients | 17 |
arrest patients | 17 |
peep cmh | 17 |
icu population | 17 |
study suggests | 17 |
oxygenation center | 17 |
requiring intensive | 17 |
extracorporeal carbon | 17 |
vad group | 17 |
main results | 17 |
herpes simplex | 17 |
oral care | 17 |
least days | 17 |
icu care | 17 |
mechanical ventilator | 17 |
average duration | 17 |
respiratory status | 17 |
may reduce | 17 |
well established | 17 |
chest radiography | 17 |
care department | 17 |
routine use | 17 |
venous thrombosis | 17 |
two years | 17 |
group received | 17 |
i min | 17 |
neutropenic patients | 17 |
considered significant | 17 |
controlled study | 17 |
potential role | 17 |
chest radiograph | 17 |
adult icu | 17 |
group versus | 17 |
regional citrate | 17 |
recent study | 17 |
mise en | 17 |
least hours | 17 |
made available | 17 |
prognostic factor | 17 |
results show | 17 |
neurologic outcome | 17 |
early mortality | 17 |
ecmo run | 17 |
heart association | 17 |
study design | 17 |
previously described | 17 |
septal defect | 17 |
surgical site | 17 |
several factors | 17 |
age groups | 17 |
diastolic dysfunction | 17 |
favorable outcome | 17 |
red cell | 17 |
risk score | 17 |
inspiratory effort | 17 |
host response | 17 |
survival prediction | 17 |
statistical difference | 17 |
plasma concentrations | 17 |
il flusso | 17 |
induced pulmonary | 17 |
major cause | 17 |
apache iii | 17 |
ecmo insertion | 17 |
venous oxygen | 17 |
one month | 16 |
con ecmo | 16 |
position paper | 16 |
weaning protocol | 16 |
ecmo services | 16 |
bed icu | 16 |
viral infection | 16 |
congenital diaphragmatic | 16 |
treatment modalities | 16 |
critical ill | 16 |
suspected infection | 16 |
coronavirus pneumonia | 16 |
trapianto polmonare | 16 |
anticoagulation strategies | 16 |
patient outcome | 16 |
old man | 16 |
insertion site | 16 |
also showed | 16 |
second day | 16 |
onset vap | 16 |
air bronchogram | 16 |
referral hospital | 16 |
receive either | 16 |
patients using | 16 |
acute severe | 16 |
platelet counts | 16 |
myocardial injury | 16 |
skeletal muscle | 16 |
emergency departments | 16 |
artificial lung | 16 |
health evaluation | 16 |
analysis revealed | 16 |
generation sequencing | 16 |
right femoral | 16 |
chikv infection | 16 |
single centre | 16 |
undergoing extracorporeal | 16 |
caloric intake | 16 |
heart transplant | 16 |
randomized trials | 16 |
supportive care | 16 |
failure due | 16 |
balloon pump | 16 |
lumen cannula | 16 |
international guidelines | 16 |
drug resistant | 16 |
mortality benefit | 16 |
attending physician | 16 |
zu einer | 16 |
gram negative | 16 |
respiratory parameters | 16 |
aged years | 16 |
ecmo pump | 16 |
questa tecnica | 16 |
organ damage | 16 |
vein thrombosis | 16 |
lung assist | 16 |
ards group | 16 |
constant flow | 16 |
higher rate | 16 |
immune cells | 16 |
neuromuscular blocking | 16 |
survival analysis | 16 |
cardiac disease | 16 |
plasma lactate | 16 |
care team | 16 |
first case | 16 |
high peep | 16 |
unit patients | 16 |
working group | 16 |
remained unchanged | 16 |
pulmonary complications | 16 |
ml cmh | 16 |
patients enrolled | 16 |
early postoperative | 16 |
saps score | 16 |
key words | 16 |
acute poisoning | 16 |
left atrial | 16 |
des canules | 16 |
mortality compared | 16 |
antibiotic prophylaxis | 16 |
pediatric population | 16 |
independent predictors | 16 |
every patient | 16 |
recently published | 16 |
pressure monitoring | 16 |
study patients | 16 |
simplex virus | 16 |
fluid bolus | 16 |
lactic acidosis | 16 |
coagulation parameters | 16 |
lung parenchyma | 16 |
clinical examination | 16 |
relative risk | 16 |
hemorrhagic stroke | 16 |
referral center | 16 |
altman analysis | 16 |
retrospective single | 16 |
treatment failure | 16 |
gastric emptying | 16 |
days following | 16 |
oxygen extraction | 16 |
real time | 16 |
postoperative complications | 16 |
controlled ventilation | 16 |
rank correlation | 16 |
necrosis factor | 16 |
cerebrospinal fluid | 16 |
anticoagulation management | 15 |
term prognosis | 15 |
children aged | 15 |
volume ventilation | 15 |
main reason | 15 |
refractaria con | 15 |
treatment group | 15 |
see table | 15 |
age range | 15 |
cardiovascular collapse | 15 |
frequent complication | 15 |
secondary analysis | 15 |
animal models | 15 |
ecmo extracorporeal | 15 |
avec une | 15 |
respiratory acidosis | 15 |
electronic health | 15 |
first episode | 15 |
hsv cmv | 15 |
en charge | 15 |
negative bacteria | 15 |
vasopressor support | 15 |
severe tbi | 15 |
strongly associated | 15 |
care hospital | 15 |
pneumonia patients | 15 |
acute heart | 15 |
confidence intervals | 15 |
predict outcome | 15 |
severe forms | 15 |
en pacientes | 15 |
previously healthy | 15 |
respiratory effort | 15 |
four groups | 15 |
cell death | 15 |
regional hospital | 15 |
ecmo va | 15 |
oxygenation extracorporeal | 15 |
may influence | 15 |
pulmonary capillary | 15 |
von willebrand | 15 |
left atrium | 15 |
increased morbidity | 15 |
respiratory complications | 15 |
double lumen | 15 |
severe cap | 15 |
experimental study | 15 |
author funder | 15 |
cesar trial | 15 |
di sangue | 15 |
adhesion molecules | 15 |
oleic acid | 15 |
large number | 15 |
lactic acid | 15 |
organ system | 15 |
acute care | 15 |
clinical experience | 15 |
cardiac arrests | 15 |
care setting | 15 |
myocardial ischemia | 15 |
study clinical | 15 |
considered statistically | 15 |
median icu | 15 |
clinical manifestations | 15 |
tumor necrosis | 15 |
pulmonary gas | 15 |
cranial trauma | 15 |
pulse pressure | 15 |
early identification | 15 |
selective pulmonary | 15 |
patient groups | 15 |
qs qt | 15 |
calculated using | 15 |
physical function | 15 |
complications occurred | 15 |
complications associated | 15 |
roc analysis | 15 |
better understand | 15 |
open heart | 15 |
hematologic malignancies | 15 |
mean pulmonary | 15 |
rrna gene | 15 |
cardiovascular complications | 15 |
associated ards | 15 |
two studies | 15 |
direct examination | 15 |
following criteria | 15 |
secondary objectives | 15 |
improves oxygenation | 15 |
consecutive adult | 15 |
international license | 15 |
initiate ecmo | 15 |
pao mmhg | 15 |
bicaval dual | 15 |
intravenous infusion | 15 |
severe traumatic | 15 |
induced ards | 15 |
blood sample | 15 |
elso guidelines | 15 |
available data | 15 |
initial dose | 15 |
sodium bicarbonate | 15 |
one week | 15 |
ecmo en | 15 |
routinely used | 15 |
mg ml | 15 |
receiving extracorporeal | 15 |
dual lumen | 15 |
complete recovery | 15 |
patients experienced | 15 |
lactate concentration | 15 |
respiratory infections | 15 |
consecutive days | 15 |
statistical differences | 15 |
plasma exchange | 15 |
old male | 15 |
return cannula | 15 |
group vs | 15 |
patients following | 15 |
lv dysfunction | 15 |
lung rest | 15 |
surgical treatment | 15 |
liquid chromatography | 15 |
oxygenator failure | 15 |
two days | 15 |
granted medrxiv | 15 |
cytokine storm | 15 |
multidisciplinary approach | 15 |
identified patients | 15 |
hemoglobin level | 15 |
tracheal pressure | 15 |
quality improvement | 15 |
positive pressure | 15 |
european society | 15 |
pregnant women | 15 |
oscillatory ventilation | 15 |
invasive aspergillosis | 15 |
influenza pneumonia | 15 |
healthcare use | 15 |
clinical variables | 15 |
lung tissue | 15 |
convalescent plasma | 15 |
non survivors | 15 |
lower limbs | 15 |
operating characteristics | 15 |
reduce mortality | 15 |
hubei province | 15 |
identify risk | 15 |
analysis using | 14 |
bed medical | 14 |
cytokine release | 14 |
drug monitoring | 14 |
may increase | 14 |
guidance document | 14 |
corresponding author | 14 |
pediatric icus | 14 |
clinical response | 14 |
genotype xxvi | 14 |
resistant bacteria | 14 |
acinetobacter baumanii | 14 |
chinese provinces | 14 |
ei outbreaks | 14 |
life threatening | 14 |
csf samples | 14 |
significant impact | 14 |
seven days | 14 |
chronic liver | 14 |
herpesviridae reactivation | 14 |
two independent | 14 |
bronchogram sign | 14 |
hypertonic saline | 14 |
acquired infections | 14 |
drainage cannula | 14 |
activated clotting | 14 |
patient presented | 14 |
complement activation | 14 |
high prevalence | 14 |
older patients | 14 |
secondary endpoints | 14 |
vascular tone | 14 |
vt ml | 14 |
minion sequencing | 14 |
patients within | 14 |
fungal infection | 14 |
may benefit | 14 |
pediatric ards | 14 |
american heart | 14 |
kcal kg | 14 |
day post | 14 |
ultraprotective ventilation | 14 |
specific treatment | 14 |
pharyngeal swab | 14 |
statistically significantly | 14 |
chest trauma | 14 |
stroke patients | 14 |
bloodstream infections | 14 |
performance category | 14 |
cerebral performance | 14 |
patient admitted | 14 |
also associated | 14 |
alveolar damage | 14 |
continuous veno | 14 |
swine fever | 14 |
fluid therapy | 14 |
terapia ecmo | 14 |
roc curves | 14 |
pediatric cardiac | 14 |
african swine | 14 |
liver cirrhosis | 14 |
illness severity | 14 |
bypass grafting | 14 |
eligible patients | 14 |
significant change | 14 |
receive ecmo | 14 |
significant proportion | 14 |
diagnostic accuracy | 14 |
post icu | 14 |
selection bias | 14 |
remains high | 14 |
potential therapeutic | 14 |
limited resources | 14 |
liver dysfunction | 14 |
ganz catheter | 14 |
respiratory extracorporeal | 14 |
ventilation time | 14 |
group iii | 14 |
pulmonary oedema | 14 |
coma score | 14 |
emerging infectious | 14 |
hospital los | 14 |
advanced age | 14 |
med doi | 14 |
guidelines recommend | 14 |
ventilatory parameters | 14 |
clinical condition | 14 |
elevated renin | 14 |
interim guidance | 14 |
frequency oscillatory | 14 |
protective mechanical | 14 |
infusion rate | 14 |
crp levels | 14 |
cox model | 14 |
transpulmonary thermodilution | 14 |
tertiary referral | 14 |
low cardiac | 14 |
independent factors | 14 |
burn injury | 14 |
information regarding | 14 |
bacterial infections | 14 |
cause mortality | 14 |
adverse outcomes | 14 |
study protocol | 14 |
receiving mechanical | 14 |
clinical criteria | 14 |
using ecmo | 14 |
influenza infection | 14 |
du co | 14 |
first study | 14 |
negative correlation | 14 |
related quality | 14 |
mean pao | 14 |
adverse drug | 14 |
lung regions | 14 |
lung ventilation | 14 |
new method | 14 |
lower incidence | 14 |
major role | 14 |
sepsis syndrome | 14 |
early experience | 14 |
pulmonary infections | 14 |
lung mechanics | 14 |
clinical symptoms | 14 |
dosing regimens | 14 |
con una | 14 |
days vs | 14 |
chikungunya virus | 14 |
cumulative dose | 14 |
segment elevation | 14 |
mit einer | 14 |
ivc diameter | 14 |
severe disease | 14 |
serum cd | 14 |
venous thromboembolism | 14 |
se sugiere | 14 |
extracorporeal circuit | 14 |
pass success | 14 |
antibiotic susceptibility | 14 |
inflammatory markers | 14 |
icu patient | 14 |
patients according | 14 |
rv lv | 14 |
transfusion requirements | 14 |
severe brain | 14 |
cerebral oxygen | 14 |
upper airway | 14 |
biological data | 14 |
missing data | 14 |
may require | 13 |
hemodynamically stable | 13 |
experimental model | 13 |
chronic lung | 13 |
en effet | 13 |
days alive | 13 |
blood components | 13 |
lumbar puncture | 13 |
therapeutic drug | 13 |
ecls support | 13 |
di ossigenazione | 13 |
elective cardiac | 13 |
per group | 13 |
regression models | 13 |
volume overload | 13 |
classified according | 13 |
della pompa | 13 |
filtration rate | 13 |
severe septic | 13 |
two pts | 13 |
tranexamic acid | 13 |
pressure mmhg | 13 |
medical management | 13 |
ventilation strategies | 13 |
sectional study | 13 |
pediatric respiratory | 13 |
consensus conference | 13 |
future studies | 13 |
last decade | 13 |
mental health | 13 |
significantly less | 13 |
breathing patients | 13 |
traumatic stress | 13 |
also significantly | 13 |
multivariable analysis | 13 |
isolated bacteria | 13 |
tecnica di | 13 |
rater reliability | 13 |
clinical relevance | 13 |
retrospective chart | 13 |
nutritional status | 13 |
repeated measures | 13 |
patients referred | 13 |
ventricular failure | 13 |
per il | 13 |
intravenous administration | 13 |
patienten mit | 13 |
arterial catheter | 13 |
lung support | 13 |
icu days | 13 |
active bleeding | 13 |
urine samples | 13 |
percutaneous dilatational | 13 |
rv failure | 13 |
adults extracorporeal | 13 |
respiratory assistance | 13 |
change significantly | 13 |
fisher exact | 13 |
high blood | 13 |
differed significantly | 13 |
thirty patients | 13 |
cardiovascular disease | 13 |
patients reported | 13 |
primary care | 13 |
patient days | 13 |
month mortality | 13 |
female sex | 13 |
cardiac transplantation | 13 |
portal vein | 13 |
failure patients | 13 |
charlson comorbidity | 13 |
ecmo care | 13 |
infectious disease | 13 |
high rates | 13 |
venous catheterization | 13 |
renal insufficiency | 13 |
died due | 13 |
twenty patients | 13 |
daily practice | 13 |
deep vein | 13 |
clinical conditions | 13 |
tertiary hospital | 13 |
care services | 13 |
aki patients | 13 |
min vs | 13 |
clinically significant | 13 |
del sangue | 13 |
emergency surgery | 13 |
three months | 13 |
right common | 13 |
ventilation settings | 13 |
kg predicted | 13 |
sodium lactate | 13 |
normal subjects | 13 |
treatment options | 13 |
deep sedation | 13 |
main objective | 13 |
without ards | 13 |
prognostic impact | 13 |
mainly due | 13 |
dans les | 13 |
oxygenation survival | 13 |
age group | 13 |
wilcoxon rank | 13 |
flail chest | 13 |
care admission | 13 |
cc kg | 13 |
literature review | 13 |
favorable neurologic | 13 |
ami patients | 13 |
solid tumors | 13 |
ventilated children | 13 |
respiratory problems | 13 |
ecmo implantation | 13 |
patients studied | 13 |
among non | 13 |
prospectively included | 13 |
ecmo course | 13 |
systemic anticoagulation | 13 |
control ventilation | 13 |
tract infections | 13 |
survivor group | 13 |
predict fluid | 13 |
clinical benefits | 13 |
research ethics | 13 |
months period | 13 |
better survival | 13 |
normal values | 13 |
require mechanical | 13 |
patients whose | 13 |
patient developed | 13 |
task force | 13 |
assisted ventilation | 13 |
intracranial bleeding | 13 |
community acquired | 13 |
pediatric icu | 13 |
failure secondary | 13 |
arterial cannula | 13 |
adult intensive | 13 |
rate variability | 13 |
ng tube | 13 |
stroke work | 13 |
mean sofa | 13 |
cell transfusion | 13 |
cardiac patients | 13 |
interstitial lung | 13 |
traditional tidal | 13 |
evaluate whether | 13 |
white cell | 13 |
data set | 13 |
positive culture | 13 |
arterial hypertension | 13 |
symptomatic treatment | 13 |
influenza patients | 13 |
healthcare workers | 13 |
therapeutic strategies | 13 |
fibrinogen concentrate | 13 |
surviving patients | 13 |
developed severe | 13 |
heart defects | 13 |
mean saps | 13 |
organ transplantation | 13 |
lipid peroxidation | 13 |
cardiovascular surgery | 13 |
oxygen transport | 13 |
respiratory drive | 13 |
aki group | 13 |
bronchial secretions | 13 |
spontaneous ventilation | 13 |
cerebral infarction | 13 |
respiratory variations | 13 |
factors related | 13 |
cases per | 13 |
secondary objective | 13 |
better outcome | 13 |
inspiratory time | 13 |
perfusion pressure | 12 |
emergency physicians | 12 |
xa activity | 12 |
less frequently | 12 |
may play | 12 |
least two | 12 |
days mortality | 12 |
feeding tube | 12 |
many patients | 12 |
decompensated heart | 12 |
improve outcomes | 12 |
highly selected | 12 |
health record | 12 |
neonatal ecmo | 12 |
mean difference | 12 |
outcome measures | 12 |
multidisciplinary ecmo | 12 |
chi square | 12 |
current guidelines | 12 |
disease control | 12 |
ohca patients | 12 |
time point | 12 |
three cases | 12 |
prise en | 12 |
postoperative day | 12 |
tissue oxygen | 12 |
protective equipment | 12 |
equine jilin | 12 |
ventilazione meccanica | 12 |
good neurological | 12 |
severe infections | 12 |
animal model | 12 |
pg kg | 12 |
version posted | 12 |
high lactate | 12 |
daily living | 12 |
clinical status | 12 |
neonatal respiratory | 12 |
registry data | 12 |
university hospitals | 12 |
local ethics | 12 |
icu syndrome | 12 |
adverse effect | 12 |
filling pressures | 12 |
potential risk | 12 |
della vena | 12 |
con covid | 12 |
ischemic injury | 12 |
immediate post | 12 |
common practice | 12 |
cd cd | 12 |
health system | 12 |
total duration | 12 |
rate increased | 12 |
induced thrombocytopenia | 12 |
significantly greater | 12 |
ecmo removal | 12 |
mortality due | 12 |
distribution width | 12 |
copd exacerbation | 12 |
blocking agents | 12 |
data show | 12 |
nutrition support | 12 |
sublingual microcirculation | 12 |
sepsis onset | 12 |
innate immunity | 12 |
inhibitory concentration | 12 |
systolic arterial | 12 |
thrombolytic therapy | 12 |
intravascular volume | 12 |
clot microstructure | 12 |
ards treated | 12 |
leg raising | 12 |
site infection | 12 |
inversely correlated | 12 |
good predictor | 12 |
science foundation | 12 |
hemodynamic stability | 12 |
phrenic nerve | 12 |
early use | 12 |
ventricular fibrillation | 12 |
fresenius medical | 12 |
initial severity | 12 |
old woman | 12 |
bei patienten | 12 |
renal recovery | 12 |
center retrospective | 12 |
low levels | 12 |
ventilator support | 12 |
higher rates | 12 |
major complications | 12 |
ng dl | 12 |
continuous intravenous | 12 |
lv function | 12 |
still alive | 12 |
three times | 12 |
antibiotic prescription | 12 |
emergency care | 12 |
lst limitation | 12 |
copyright holder | 12 |
saudi arabia | 12 |
early administration | 12 |
previous reports | 12 |
posted october | 12 |
physical examination | 12 |
muscle strength | 12 |
serum concentration | 12 |
despite optimal | 12 |
right atrial | 12 |
mesenteric ischemia | 12 |
fluid removal | 12 |
expected mortality | 12 |
graft failure | 12 |
neonatal intensive | 12 |
acute cerebral | 12 |
va ecls | 12 |
data available | 12 |
fungal infections | 12 |
flusso sanguigno | 12 |
red cells | 12 |
protocol group | 12 |
glasgow score | 12 |
online version | 12 |
underwent cardiac | 12 |
cumulative incidence | 12 |
influenza surveillance | 12 |
early recognition | 12 |
assistenza respiratoria | 12 |
potential benefits | 12 |
one patients | 12 |
median number | 12 |
mean total | 12 |
using extracorporeal | 12 |
may reflect | 12 |
also found | 12 |
chronic hepatitis | 12 |
venous catheters | 12 |
cardiac support | 12 |
increasingly used | 12 |
complication rate | 12 |
icu setting | 12 |
multiorgan dysfunction | 12 |
prothrombin time | 12 |
limited data | 12 |
transpulmonary pressure | 12 |
final diagnosis | 12 |
different types | 12 |
retrospective case | 12 |
qualitative data | 12 |
cerebral edema | 12 |
outcomes included | 12 |
passive leg | 12 |
clinical use | 12 |
cardiac injury | 12 |
good correlation | 12 |
kidney function | 12 |
diastolic function | 12 |
serum sodium | 12 |
acute asthma | 12 |
narrative review | 12 |
mean weight | 12 |
organ perfusion | 12 |
among critically | 12 |
bayesian analysis | 12 |
successfully treated | 12 |
every day | 12 |
pulmonary vasoconstriction | 12 |
study extracorporeal | 12 |
laboratory tests | 12 |
ards requiring | 12 |
invasive procedure | 12 |
di gas | 12 |
ethical committee | 12 |
ibn rochd | 12 |
median delay | 12 |
another hospital | 12 |
cystic fibrosis | 12 |
hsv reactivation | 12 |
hypovolemic shock | 12 |
bleeding events | 12 |
local signs | 12 |
strong correlation | 12 |
icu acquired | 12 |
arterial cannulation | 12 |
fluid loading | 12 |
ethics approval | 12 |
phase i | 12 |
limb ischemia | 12 |
neurological status | 12 |
intensive therapy | 12 |
repeated measurements | 12 |
old female | 12 |
peripheral cannulation | 12 |
therapeutic interventions | 12 |
epidemiological characteristics | 12 |
additional information | 12 |
major abdominal | 12 |
innate immune | 12 |
mean icu | 12 |
airway resistance | 12 |
machine learning | 12 |
abdominal sepsis | 12 |
medical students | 12 |
hours post | 12 |
refractory shock | 12 |
elective surgery | 12 |
nasogastric tube | 12 |
cox regression | 12 |
common causes | 12 |
flow oxygen | 12 |
position ventilation | 12 |
main reasons | 12 |
adequate oxygenation | 12 |
first line | 12 |
function tests | 12 |
broad spectrum | 12 |
simulation training | 12 |
tissue hypoxia | 12 |
care syndrome | 12 |
gastrointestinal tract | 12 |
patients met | 12 |
new york | 12 |
clinical efficacy | 12 |
resistance index | 12 |
physiological parameters | 12 |
risk assessment | 12 |
early pp | 12 |
lv filling | 12 |
kingdom critical | 12 |
circulatory shock | 12 |
physical therapy | 12 |
prediction model | 12 |
third day | 12 |
alveolar lavage | 12 |
severe aki | 12 |
continuous positive | 12 |
fulminant myocarditis | 12 |
experimental studies | 12 |
trend towards | 12 |
age yrs | 12 |
successful treatment | 12 |
severe cardiopulmonary | 12 |
death rate | 12 |
endothelial cell | 12 |
developing countries | 12 |
secondary outcome | 12 |
chronic heart | 12 |
lung infection | 12 |
secondary infections | 12 |
three years | 12 |
subarachnoid hemorrhage | 12 |
affiliated hospital | 12 |
early sepsis | 12 |
previously published | 12 |
early extubation | 12 |
therapeutic failure | 12 |
supplemental oxygen | 12 |
low rate | 12 |
much higher | 12 |
useful tool | 12 |
plasma samples | 11 |
factors independently | 11 |
moderate ards | 11 |
baseline levels | 11 |
serum concentrations | 11 |
inspiratory flow | 11 |
reasonable request | 11 |
medical patients | 11 |
two decades | 11 |
reactive oxygen | 11 |
hemodynamic measurements | 11 |
amino acid | 11 |
organ dysfunctions | 11 |
glomerular filtration | 11 |
early mobilization | 11 |
eligibility criteria | 11 |
personal protective | 11 |
temperature management | 11 |
reverse transcription | 11 |
underlying malignancy | 11 |
common carotid | 11 |
glass opacities | 11 |
increasing use | 11 |
patients will | 11 |
ductus arteriosus | 11 |
strong association | 11 |
va mode | 11 |
fatal asthma | 11 |
took place | 11 |
failure extracorporeal | 11 |
antibiotic use | 11 |
body surface | 11 |
linear mixed | 11 |
clinical improvement | 11 |
drug interactions | 11 |
blood oxygenation | 11 |
auf die | 11 |
dna levels | 11 |
cytomegalovirus reactivation | 11 |
nach der | 11 |
subgroup analysis | 11 |
positive effect | 11 |
kidney transplantation | 11 |
matched analysis | 11 |
nan title | 11 |
hiv patients | 11 |
control subjects | 11 |
mait cells | 11 |
animal experiments | 11 |
major adverse | 11 |
standardized protocol | 11 |
grant acknowledgment | 11 |
vad support | 11 |
lower risk | 11 |
natural science | 11 |
kdigo criteria | 11 |
severe complication | 11 |
higher apache | 11 |
el grupo | 11 |
hour period | 11 |
chest physiotherapy | 11 |
per se | 11 |
serum level | 11 |
whole body | 11 |
postoperative care | 11 |
static compliance | 11 |
membrane oxygenators | 11 |
trial extracorporeal | 11 |
susceptibility testing | 11 |
early post | 11 |
many studies | 11 |
pulse contour | 11 |
willebrand factor | 11 |
outcome measure | 11 |
par une | 11 |
invasive procedures | 11 |
support may | 11 |
cannula di | 11 |
final manuscript | 11 |
prior antibiotic | 11 |
team members | 11 |
multicenter retrospective | 11 |
subclavian vein | 11 |
elso guidance | 11 |
transplantation extracorporeal | 11 |
interim guidelines | 11 |
decompressive craniectomy | 11 |
respiratory illness | 11 |
patients years | 11 |
apache score | 11 |
time interval | 11 |
using standard | 11 |
academic medical | 11 |
gastrointestinal bleeding | 11 |
prospective data | 11 |
arterial hypotension | 11 |
respiratory viruses | 11 |
icu healthcare | 11 |
supported ventilation | 11 |
hemodynamic failure | 11 |
system compliance | 11 |
investigated whether | 11 |
complications including | 11 |
lymphocyte count | 11 |
carbapenem resistance | 11 |
ct scans | 11 |
ventilator setting | 11 |
ml cm | 11 |
first two | 11 |
secretion clearance | 11 |
preliminary study | 11 |
functional residual | 11 |
pneumonia caused | 11 |
practice guidelines | 11 |
hemodynamic support | 11 |
par ailleurs | 11 |
total respiratory | 11 |
aortic cross | 11 |
better outcomes | 11 |
remains unknown | 11 |
il sangue | 11 |
data obtained | 11 |
management strategies | 11 |
respiratory ecls | 11 |
acute illness | 11 |
ecls patients | 11 |
patient group | 11 |
dynamic compliance | 11 |
longer icu | 11 |
lactate clearance | 11 |
il rischio | 11 |
using logistic | 11 |
one episode | 11 |
myocardial function | 11 |
characteristic curve | 11 |
resp score | 11 |
last two | 11 |
mv duration | 11 |
prognostic marker | 11 |
ventilatory management | 11 |
way anova | 11 |
hemodynamic effects | 11 |
underlying diseases | 11 |
myocardial oxygen | 11 |
studies reported | 11 |
survival time | 11 |
cell distribution | 11 |
nasal oxygen | 11 |
random order | 11 |
serum potassium | 11 |
south african | 11 |
first pass | 11 |
work load | 11 |
ecmo management | 11 |
frequently associated | 11 |
escherichia coli | 11 |
septic complications | 11 |
chronic dysglycemia | 11 |
observation period | 11 |
retrospectively studied | 11 |
requiring icu | 11 |
depression scale | 11 |
new onset | 11 |
one child | 11 |
case basis | 11 |
relatively low | 11 |
respiratory depression | 11 |
par le | 11 |
induced changes | 11 |
preload responsiveness | 11 |
sepsis septic | 11 |
french icus | 11 |
extracorporeal gas | 11 |
vasodilatory shock | 11 |
risk group | 11 |
comatose patients | 11 |
residual capacity | 11 |
lv ratio | 11 |
mpm ii | 11 |
randomized prospective | 11 |
anaerobic metabolism | 11 |
false positive | 11 |
cardiac catheterization | 11 |
class i | 11 |
extracorporeal oxygenation | 11 |
two main | 11 |
early albumin | 11 |
high volume | 11 |
young children | 11 |
volume controlled | 11 |
effective method | 11 |
first attempt | 11 |
past years | 11 |
confirmed covid | 11 |
clinical frailty | 11 |
predicted mortality | 11 |
co production | 11 |
spectrum antibiotics | 11 |
venous drainage | 11 |
low risk | 11 |
hospital admissions | 11 |
antimicrobial susceptibility | 11 |
increased levels | 11 |
different levels | 11 |
percutaneous cannulation | 11 |
related factors | 11 |
data showed | 11 |
streptococcus pneumoniae | 11 |
clinical impact | 11 |
room air | 11 |
patients due | 11 |
monitoring system | 11 |
lung water | 11 |
patient received | 11 |
comorbidity index | 11 |
near infrared | 11 |
pulmonary fibrosis | 11 |
troponin i | 11 |
expiratory flow | 11 |
magnetic resonance | 11 |
first postoperative | 11 |
patient demographics | 11 |
des cas | 11 |
free radicals | 11 |
oxidative stress | 11 |
bei der | 11 |
failure rate | 11 |
trend toward | 11 |
vascular resistances | 11 |
sur les | 11 |
single dose | 11 |
remained stable | 11 |
inspiratory pressures | 11 |
following icu | 11 |
impedance tomography | 11 |
ml respectively | 11 |
limited evidence | 11 |
serum bilirubin | 11 |
systemic circulation | 11 |
intrinsic peep | 11 |
management system | 11 |
potentially reversible | 11 |
health workers | 11 |
may facilitate | 11 |
five cases | 11 |
log rank | 11 |
influenza subtype | 10 |
rv afterload | 10 |
median apache | 10 |
high tidal | 10 |
alveolar recruitment | 10 |
worse outcome | 10 |
hcv subtype | 10 |
years period | 10 |
oxygen flow | 10 |
patient underwent | 10 |
rischio di | 10 |
suspected bacterial | 10 |
healthcare providers | 10 |
kept constant | 10 |
term mechanical | 10 |
upper gi | 10 |
ecmo specialist | 10 |
disease process | 10 |
therapeutic strategy | 10 |
hemodynamic data | 10 |
positive results | 10 |
international multicenter | 10 |
transport team | 10 |
diastolic blood | 10 |
following cardiac | 10 |
diaphragm thickness | 10 |
volume status | 10 |
relative humidity | 10 |
antibacterial therapy | 10 |
significant mortality | 10 |
one way | 10 |
studies showed | 10 |
neutrophil activation | 10 |
initial experience | 10 |
en particulier | 10 |
ecmo vv | 10 |
peritoneal dialysis | 10 |
international ecmo | 10 |
bloodstream infection | 10 |
serious infections | 10 |
important factor | 10 |
domestic poultry | 10 |
liver enzymes | 10 |
operative complications | 10 |
significantly shorter | 10 |
randomized control | 10 |
clinical suspicion | 10 |
neurologic complications | 10 |
thirteen patients | 10 |
higher sofa | 10 |
less severe | 10 |
clinical research | 10 |
dic score | 10 |
ecmo veino | 10 |
improve patient | 10 |
required invasive | 10 |
capillary leak | 10 |
artificial ventilation | 10 |
severe complications | 10 |
successfully extubated | 10 |
significantly better | 10 |
financial support | 10 |
negative impact | 10 |
administered intravenously | 10 |
lateral position | 10 |
improve oxygenation | 10 |
time constant | 10 |
ventricular systolic | 10 |
commercially available | 10 |
icu nurse | 10 |
le recours | 10 |
systemic oxygen | 10 |
cardiorespiratory failure | 10 |
niv hfnc | 10 |
post traumatic | 10 |
peep positive | 10 |
indirect calorimetry | 10 |
orotracheal intubation | 10 |
thoracic aorta | 10 |
antibiotic resistance | 10 |
may allow | 10 |
respiratory ecmo | 10 |
may impact | 10 |
immune dysfunction | 10 |
hand hygiene | 10 |
multicenter randomized | 10 |
dal flusso | 10 |
und der | 10 |
day one | 10 |
thrombotic events | 10 |
purulent pericarditis | 10 |
disease clinical | 10 |
within min | 10 |
brain blood | 10 |
three hours | 10 |
fr annals | 10 |
urea nitrogen | 10 |
observational studies | 10 |
venous cannulation | 10 |
cuff pressure | 10 |
mean dose | 10 |
weaning trial | 10 |
also evaluated | 10 |
ecmo remains | 10 |
blood cyanide | 10 |
filling pressure | 10 |
successfully used | 10 |
prolonged ecmo | 10 |
fio decreases | 10 |
deleterious effects | 10 |
postpartum patients | 10 |
clinical significance | 10 |
anova test | 10 |
cerebral oedema | 10 |
two methods | 10 |
volume curve | 10 |
breaths per | 10 |
systemic pressure | 10 |
blood group | 10 |
disk diffusion | 10 |
ecmo survivors | 10 |
une ventilation | 10 |
southernmost provinces | 10 |
conventional methods | 10 |
cases reported | 10 |
avec un | 10 |
supportive therapy | 10 |
una tecnica | 10 |
ascending aorta | 10 |
pulmonary compliance | 10 |
rv systolic | 10 |
staff members | 10 |
cci patients | 10 |
igs ii | 10 |
clinical diagnosis | 10 |
sedative drugs | 10 |